Contineum Therapeutics (CTNM) closed at $9.86 on November 13, 2026, up 0.8% from the previous close, on volume of 257,129 shares (30-day average 1,023,487).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 28, 2026 | Diagonal Call Spread | 15-Jan : 17-Jun-2715 : 10 C | 4,500 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
No headlines found.
Business Wire (Mon, 9-Nov 4:35 AM ET)
Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
Business Wire (Tue, 3-Nov 4:05 PM ET)
Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference
Business Wire (Thu, 29-Oct 4:05 PM ET)
Business Wire (Mon, 14-Sep 4:05 PM ET)
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
Business Wire (Tue, 25-Aug 4:05 PM ET)
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Contineum Therapeutics trades on the NASDAQ stock market under the symbol CTNM.
As of November 13, 2026, CTNM stock price climbed to $9.86 with 257,129 million shares trading.
CTNM has a beta of 1.04, meaning it tends to be more sensitive to market movements. CTNM has a correlation of 0.02 to the broad based SPY ETF.
CTNM has a market cap of $370.94 million. This is considered a Small Cap stock.
Last quarter Contineum Therapeutics reported $0 in Revenue and -$.49 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.04.
The top ETF exchange traded funds that CTNM belongs to (by Net Assets): VTI, IWM, VXF, XPH, IWN.
CTNM has underperformed the market in the last year with a return of -9.5%, while the SPY ETF gained +13.4%. In the last 3 month period, CTNM fell short of the market, returning -35.6%, while SPY returned -2.8%. However, in the most recent 2 weeks CTNM has outperformed the stock market by returning +5.0%, while SPY returned -0.2%.
CTNM support price is $9.17 and resistance is $10.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTNM shares will trade within this expected range on the day.